PubMed HealthSearch

Biomedical subjects

Liviu M Mirica

Publications and source records attributed to Liviu M Mirica.

2 recordsLinked to original sources

Cu(II/I)-Pyridinophane Complexes: O2 Reactivity and 64Cu PET Imaging Studies.

The redox versatility of copper between the Cu(I) and Cu(II) oxidation states is central to its function in a variety of biological processes, including electron transfer, oxygen transport, and redox catalysis by metalloenzymes. Motivated by these biological paradigms, we report the design and development of a new series of chelators based on the 2-aza[3,2](2,6)pyridinophane (RN3) ligands (RN3, R = H, Me, 2-methylpyridyl, and 2-methylpicolinate). These ligands are designed to replicate key features of metalloenzyme active sites and to modulate the copper coordination environment. The new RN3 ligands have been fully characterized by NMR spectroscopy, high-resolution mass spectrometry, and UV-vis spectrophotometric titrations. The Cu(I) and Cu(II) complexes supported by these ligands were synthesized and characterized structurally and spectroscopically to investigate the effects of ligand denticity, variation in donor atoms, and chelate ring size on coordination geometry, bond parameters, and redox behavior. Special attention is given to the reactivity of Cu(I) complexes toward O2, offering insights into pathways of O2 activation and reduction. The RN3 ligands also demonstrate promising stability and binding affinity for both Cu(II) and Cu(I) ions, underscoring their potential for 64Cu-based positron emission tomography (PET) imaging applications.

Journal Article

Donepezil and Memantine Derivatives for Dual-Function and Prodrug Applications in Alzheimer's Disease.

The treatment of Alzheimer's disease by acetylcholinesterase (AChE) and N-methyl-d-aspartate receptor (NMDAR) inhibitors is limited by the narrow therapeutic window and adverse side effects of the drugs. This study aims to increase the efficacy and limit the side effects of donepezil, an AChE inhibitor, and memantine, an NMDAR inhibitor, through the addition of amyloid-β (Aβ)-targeting fragments to create dual-function compounds. The incorporation of the amyloid-targeting fragments successfully produced compounds with affinity for Aβ fibrils, and that can stain amyloid plaques in the brains of 5xFAD mice. The donepezil-based compounds showed significant changes in AChE inhibition compared to donepezil due to the incorporation of the Aβ-targeting fragment and as confirmed by molecular docking studies. The memantine-derived compound showed good brain uptake in 5xFAD mice but lacked compatibility with NMDAR inhibition based on in vitro assays and molecular docking. Importantly, the memantine-derived compound acts as a prodrug in vivo, releasing memantine within a pharmacologically relevant time frame. Overall, these findings suggest that dual-function compounds may be useful as drug delivery agents that can be metabolized to release an active drug in areas of the brain rich in amyloid plaques and thus could lead to improved treatments for Alzheimer's disease.

Animals